P3.02c-066 HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
نویسندگان
چکیده
منابع مشابه
Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer
In the past several years, immunotherapy has emerged as a viable treatment option for patients with advanced non-small cell lung cancer (NSCLC) without actionable driver mutations that have progressed on standard chemotherapy. We are also beginning to understand the methods of immune evasion employed by NSCLC which likely contribute to the 20% response rate to immunotherapy. It is also yet uncl...
متن کاملImmune Checkpoint Inhibitors in Advanced-Stage Non-small Cell Lung Cancer.
More than half of non-small cell lung cancer (NSCLC) patients are at an advanced stage at the time of diagnosis, and they have a poor prognosis. Systemic treatment is the basic treatment approach for advanced-stage NSCLC, and chemotherapy and targeted treatments are commonly used based on the molecular characteristics. Although targeted therapies have led to a significant level of improvement i...
متن کاملphase ii study of gemcitabine and cisplatin regimen in advanced non-small cell lung cancer (nsclc).
background: cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (nsclc). many novel drugs, including gemcitabine, vinorelbine, paclitaxel and docetaxel have been used in combination with cisplatin in this setting. of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. the aim of this study was to evaluate the effi...
متن کاملImmune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets
Lung cancer is the leading cause of cancer-related deaths in the world. Immune checkpoint inhibitors (ICI) stimulate cytotoxic lymphocyte activity against tumour cells. These agents are available for the treatment of non-small cell lung cancer (NSCLC) after failure of platinum-based therapy. One recent study has demonstrated that ICI monotherapy was superior to platinum-based chemotherapy for f...
متن کاملMulti-target inhibitors in non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer death world-wide [1]. Current treatment modalities, including chemotherapy, radiotherapy and surgery, have provided only limited improvement in the natural course of this disease. Therefore, the development of new therapeutic strategies is highly awaited [2]. In the last years, there has been an explosion in the knowledge of the genetic and biologic un...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.1861